Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd.
Your view on OPHLF
Overview
What the company does, where it operates, and who runs it.
About Ono Pharmaceutical Co., Ltd.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Gyo Sagara
- Headquarters
- 8-2, Kyutaromachi 1-chome, Osaka, JP
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Gyo Sagara
- Headquarters
- 8-2, Kyutaromachi 1-chome, Osaka, JP
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide.
It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors.
The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis.
In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis.
The company was founded in 1717 and is headquartered in Osaka, Japan.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Ono Pharmaceutical Co., Ltd., and the rating behind it. OPHLF last traded at $16.70, 14.3× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Ono Pharmaceutical Co., Ltd.. Starting points for Ono Pharmaceutical Co., Ltd.: P/E 14.3, EPS $162.43, beta 0.04 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Ono Pharmaceutical Co., Ltd.. Ono Pharmaceutical Co., Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Ono Pharmaceutical Co., Ltd.. Trailing twelve-month EPS for Ono Pharmaceutical Co., Ltd. stands at $162.43. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Ono Pharmaceutical Co., Ltd.. Ono Pharmaceutical Co., Ltd. has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Ono Pharmaceutical Co., Ltd. valued side by side against its closest peers. Ono Pharmaceutical Co., Ltd. is measured against Drug Manufacturers - General peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Ono Pharmaceutical Co., Ltd., and how their positions are changing. At a $7.85B market value, institutional positions materially move Ono Pharmaceutical Co., Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Ono Pharmaceutical Co., Ltd. executives and directors. Shares of Ono Pharmaceutical Co., Ltd. have traded between $9.20 and $18.67 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Ono Pharmaceutical Co., Ltd.. Ono Pharmaceutical Co., Ltd. is a $7.85B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Ono Pharmaceutical Co., Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Ono Pharmaceutical Co., Ltd.. Coverage tracks Ono Pharmaceutical Co., Ltd. within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.